Post-stroke hyperglycaemia – Treatment with Exenatide in Acute Ischaemic Stroke (TEXAIS) trial

中风后高血糖 — 急性缺血性中风 (TEXAIS) 试验中艾塞那肽治疗

• 批准号: nhmrc : GNT1126070
• 负责人: A/Pr Elif Ekinci
• 金额: $ 126.61万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/post-stroke-hyperglycaemia-texais-trial/1347527
• 关键词: Post; stroke; hyperglycaemia; Treatment; Exenatide

Raised blood glucose levels (hyperglycaemia) after a stroke is common. It reduces the efficacy of stroke treatments and results in worse outcomes. Insulin is not useful as a treatment for this as it causes frequent hypoglycaemia and does not improve clinical outcomes. Exenatide is a common diabetes drug that is simple to use and lowers blood glucose without hypoglycaemia. It will be tested in the Treatment with Exenatide in Acute Ischaemic Stroke (TEXAIS) trial.

中风后血糖升高（高血糖）是很常见的。它降低了中风治疗的效果，并导致更糟糕的结果。胰岛素不能作为一种有效的治疗方法，因为它会引起频繁的低血糖，并不能改善临床结果。艾塞那肽是一种常用的糖尿病药物，使用简单，可降低血糖而无低血糖。它将在艾塞那肽治疗急性缺血性卒中（TEXAIS）试验中进行测试。